{"title":"The relationship between folic acid and nonalcoholic fatty liver disease","authors":"Bing'er Xu, Xinyu Yang, Xiaopeng Zhu, Qiling Liu, Yuying Zhang, Miao Zhang, Chenmin Fan, Xilei Ban, Guligeina Aikebaier, Hua bian","doi":"10.1002/ctd2.274","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>In recent years, the incidence of non-alcoholic fatty liver disease (NAFLD) has been increasing, which has become an explosive interest because of the growing impact on world health. NAFLD is the hepatic manifestation of systemic metabolic syndrome (MS), and the umbrella term that comprises a continuum of liver conditions, from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), has a variable course but can lead to cirrhosis and hepatocellular carcinoma (HCC). currently, there is no pharmacological agent that is therapeutically approved for the treatment of this disease. Folic acid (FA) was one of a water-soluble B vitamins, entirely absorbed from the diet. Numbers of clinical studies have confirmed that patients with NAFLD and insulin resistance are often accompanied by abnormal FA. We investigated the potential effects of FA on NAFLD through the metabolic pathways, DNA synthesis and methylation, oxidative stress in liver and intestinal flora. In addition, FA has an effect on HCC or other cancer. Therefore, FA might be a safe and economical potential treatment method for NAFLD.</p>\n </section>\n </div>","PeriodicalId":72605,"journal":{"name":"Clinical and translational discovery","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctd2.274","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and translational discovery","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ctd2.274","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In recent years, the incidence of non-alcoholic fatty liver disease (NAFLD) has been increasing, which has become an explosive interest because of the growing impact on world health. NAFLD is the hepatic manifestation of systemic metabolic syndrome (MS), and the umbrella term that comprises a continuum of liver conditions, from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), has a variable course but can lead to cirrhosis and hepatocellular carcinoma (HCC). currently, there is no pharmacological agent that is therapeutically approved for the treatment of this disease. Folic acid (FA) was one of a water-soluble B vitamins, entirely absorbed from the diet. Numbers of clinical studies have confirmed that patients with NAFLD and insulin resistance are often accompanied by abnormal FA. We investigated the potential effects of FA on NAFLD through the metabolic pathways, DNA synthesis and methylation, oxidative stress in liver and intestinal flora. In addition, FA has an effect on HCC or other cancer. Therefore, FA might be a safe and economical potential treatment method for NAFLD.
近年来,非酒精性脂肪肝(NAFLD)的发病率不断上升,对世界健康的影响日益增大,因而引起了人们的极大关注。非酒精性脂肪肝是全身代谢综合征(MS)的肝脏表现,是由非酒精性脂肪肝(NAFL)到非酒精性脂肪性肝炎(NASH)等一系列肝脏疾病组成的总称,病程多变,但可导致肝硬化和肝细胞癌(HCC)。叶酸(FA)是一种水溶性 B 族维生素,可完全从饮食中吸收。大量临床研究证实,非酒精性脂肪肝和胰岛素抵抗患者通常伴有叶酸异常。我们通过新陈代谢途径、DNA 合成和甲基化、肝脏氧化应激和肠道菌群,研究了 FA 对非酒精性脂肪肝的潜在影响。此外,FA 对 HCC 或其他癌症也有影响。因此,FA 可能是一种安全、经济的治疗非酒精性脂肪肝的潜在方法。